Identified polypharmacy as a significant risk factor for cognitive decline
Suggested that structured medication management can mitigate cognitive decline
Showed a correlation between polypharmacy levels and worsening cognitive function.
Resumen
Our findings highlight polypharmacy as a key, modifiable risk for cognitive decline in AD, calling for structured medication management to mitigate this risk.